COVID-19: A Mulicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with Acute Respiratory Distress Syndrome Associated with COVID-19

Date Added
April 8th, 2021
PRO Number
Pro00109695
Researcher
Andrew Goodwin

List of Studies


Keywords
Coronavirus, Drug Studies, Infectious Diseases, Lung, Pulmonary, SARS-CoV-2
Summary

TESICO (Therapeutics for Severely Ill Inpatients with COVID-19) is a master protocol to evaluate the safety and efficacy of investigational agents aimed at improving outcomes for patients with acute respiratory failure related to COVID-19.

Institution
MUSC
Recruitment Contact
Abigail Grady
843-792-2072
gradyabi@musc.edu

COVID-19: Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study

Date Added
October 15th, 2020
PRO Number
Pro00103211
Researcher
Andrew Goodwin

List of Studies


Keywords
Coronavirus, Infectious Diseases, Lung, Pulmonary, SARS-CoV-2
Summary

BLUE CORAL is an observational, biorepository study for patients who are hospitalized with COVID-19. The study collects various data and biospecimens, such as blood, urine, and tracheal aspirates, during the patient's hospital stay. The data and biospecimens collected will be used to provide greater knowledge on the biology and epidemiology of COVID-19.

Institution
MUSC
Recruitment Contact
Abigail Grady
843-792-2072
gradyabi@musc.edu

Assessing prior SARS-CoV-2 infection among the general population in Charleston, South Carolina: a community seroprevalence study

Date Added
September 1st, 2020
PRO Number
Pro00103008
Researcher
Michael Sweat

List of Studies


Keywords
COVID-19, Coronavirus, Infectious Diseases, Non-interventional, SARS-CoV-2
Summary

Understanding the current epidemiology of COVID-19 is of urgent importance in light of the continued pandemic. Given current testing guidelines, the number of individuals within the Charleston, South Carolina area who have had COVID-19 is unknown. Many such individuals may have been asymptomatic or mildly symptomatic. Thus, the number of confirmed cases, those who are or have been symptomatic and tested for COVID-19, is most likely a significant underrepresentation of the community seroprevalence of the virus. The purpose of this study is to determine the number of prior COVID-19 infections that are present in the Charleston area among adults, and to evaluate characteristics associated with infection with SARS-CoV-2, the virus which causes COVID-19.

Institution
MUSC
Recruitment Contact
Michael Sweat
843-876-1082
sweatm@musc.edu

Colonizing Microbiome as a Determinant of COVID-19 Outcome

Date Added
August 4th, 2020
PRO Number
Pro00102644
Researcher
Alexander Alekseyenko

List of Studies


Keywords
Coronavirus, Immune System, Infectious Diseases, Non-interventional, SARS-CoV-2
Summary

COVID-19 testing involves collection of swabs from nasopharyngeal cavities where the SARS-CoV-2 virus replicates. Many other commensal and pathogenic microbes may be found in the same host niche. Collectively, these microbes are called the microbiome. We hypothesize that the colonizing microbiome at the time of diagnosis may provide leads for early stratification of cases into risk categories, future clinical manifestations of the disease, and insights into treatment strategies.

Institution
MUSC
Recruitment Contact
Bashir Hamidi
843-792-8657
hamidib@musc.edu

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19

Date Added
June 24th, 2020
PRO Number
Pro00101116
Researcher
Eric Meissner

List of Studies


Keywords
Coronavirus, SARS-CoV-2
Summary

This is a study to see if an intravenous (IV) infusion of medication: REGN10933+REGN10987 is an effective and safe treatment for COVID-19. REGN10933+REGN10987 is an investigational medication which means they have not been approved by the FDA to treat COVID-19 or any other disease. Adult patients who are not hospitalized with COVID-19 (i.e. outpatient or ambulatory) and have COVID-19 symptoms may be eligible for this study. Participants will be randomly assigned to receive a onetime infusion of the medication or placebo. Study participation will last about 4 weeks and may include home home-based visits.

Institution
MUSC
Recruitment Contact
Angela Millare
843-792-3710
millare@musc.edu

SCTR / MUSC COVID-19 Biorepository

Date Added
April 16th, 2020
PRO Number
Pro00098961
Researcher
Patrick Flume

List of Studies


Keywords
COVID-19, Coronavirus, Infectious Diseases, Men's Health, Non-interventional, SARS-CoV-2, Women's Health
Summary

The Medical University of South Carolina (MUSC) is developing a COVID-19 biorepository which will contain blood, urine, and other bodily fluids along with relevant medical information from individuals evaluated, exposed to, or treated for COVID-19. To learn from this pandemic ,and to develop treatments and strategies to better prepare and avert future pandemics we must study the disease and its effects. The clinical specimens in the biorepository will be available for investigators to use for future research. Compensation is provided for participation in this project for eligible participants.

Institution
MUSC
Recruitment Contact
Lauren Card
843-729-4394
coordinator@musc.edu



-- OR --